1. Selective depletion of a CD64-expressing phagocyte subset mediates protection against toxic kidney injury and failure
- Author
-
Markus Moser, Barbara U. Schraml, Vanessa Kuentzel, Natallia Salei, Dalia Pakalniškytė, Thorsten Buch, Katja Steiger, Xingqi Ji, Na Li, Hans-Joachim Anders, Stephan Rambichler, University of Zurich, and Schraml, Barbara U
- Subjects
Male ,Phagocyte ,cisplatin ,CD11c ,Antineoplastic Agents ,610 Medicine & health ,Biology ,Monocytes ,necroinflammation ,Mice ,Immunology and Inflammation ,Immune system ,medicine ,Animals ,10239 Institute of Laboratory Animal Science ,Receptor ,Tissue homeostasis ,Mice, Knockout ,Phagocytes ,1000 Multidisciplinary ,Kidney ,Multidisciplinary ,Macrophages ,Receptors, IgG ,Acute kidney injury ,Dendritic Cells ,Acute Kidney Injury ,Biological Sciences ,medicine.disease ,ddc ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Cancer research ,570 Life sciences ,biology ,590 Animals (Zoology) ,Female ,Heparin-binding EGF-like Growth Factor ,Kidney disease - Abstract
Significance There continues to be a paucity in models to target mononuclear phagocyte (MP) subsets selectively and in specific tissues. We report a mouse model allowing for selective depletion of a specific subset of kidney MPs that is based on a Cre-inducible lox-STOP-lox-diphtheria toxin receptor gene controlled by the endogenous CD64 promoter. Combined with specific targeting of conventional DC1 (cDC1) and cDC2, we revealed that CD64+ MPs account for the reported ability of CD11c+ cells to limit cisplatin nephrotoxicity, while cDC1 and cDC2 are dispensable. Our study highlights that individual MP subsets have unique functions in kidney pathology. Combined with various CRE drivers, CD64-lox-STOP-lox-diphtheria toxin receptor mice might be used to study CD64-expressing cells in other tissues., Dendritic cells (DC), macrophages, and monocytes, collectively known as mononuclear phagocytes (MPs), critically control tissue homeostasis and immune defense. However, there is a paucity of models allowing to selectively manipulate subsets of these cells in specific tissues. The steady-state adult kidney contains four MP subsets with Clec9a-expression history that include the main conventional DC1 (cDC1) and cDC2 subtypes as well as two subsets marked by CD64 but varying levels of F4/80. How each of these MP subsets contributes to the different phases of acute kidney injury and repair is unknown. We created a mouse model with a Cre-inducible lox-STOP-lox-diphtheria toxin receptor cassette under control of the endogenous CD64 locus that allows for diphtheria toxin–mediated depletion of CD64-expressing MPs without affecting cDC1, cDC2, or other leukocytes in the kidney. Combined with specific depletion of cDC1 and cDC2, we revisited the role of MPs in cisplatin-induced kidney injury. We found that the intrinsic potency reported for CD11c+ cells to limit cisplatin toxicity is specifically attributed to CD64+ MPs, while cDC1 and cDC2 were dispensable. Thus, we report a mouse model allowing for selective depletion of a specific subset of renal MPs. Our findings in cisplatin-induced injury underscore the value of dissecting the functions of individual MP subsets in kidney disease, which may enable therapeutic targeting of specific immune components in the absence of general immunosuppression.
- Published
- 2021